Welcome to our dedicated page for Balance Labs SEC filings (Ticker: BLNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Balance Labs, Inc. (BLNC) SEC filings page provides access to the company’s regulatory disclosures, including current reports that describe significant corporate events. Balance Labs is a consulting firm that focuses on incubator and accelerator services for start-up and development stage companies and has stated that it is working on a repeatable digital asset strategy. Its SEC filings offer additional detail on governance and material developments beyond brief press announcements.
Among the filings, Balance Labs has submitted a Form 8-K reporting changes in its board of directors. The filing states that on December 12, 2025, Carmen Villegas resigned as a member of the board of directors, effective immediately, and notes that her resignation was not the result of any disagreement with the company regarding operations, policies, practices, controls, or financial-related matters. Such disclosures help investors understand changes in oversight and governance.
Through this page, users can review Balance Labs’ current reports and other SEC documents as they become available from EDGAR. AI-powered summaries can assist by highlighting the key points in lengthy filings, explaining the significance of items such as director resignations or other reported events in clearer language. This allows readers to quickly identify the main subjects of each filing and then consult the full text for complete details.
Balance Labs, Inc. has appointed Alexander Farkas as President and Chief Operating Officer, effective February 9, 2026. He brings experience from EV charging, military engineering, capital markets, digital assets, and solar-energy project financing, which the company notes aligns with its multi-line digital-asset operating focus.
The President Offer Letter provides an annual base salary of $120,000, with a target bonus of 65% of base salary and potential bonus of up to 125% of base salary, which he may elect to receive in common stock. The agreement has an initial two-year term with automatic two-year renewals and includes three months of base-salary continuation and COBRA benefits upon termination without cause or for good reason. Farkas is also subject to non-competition and other restrictive covenants and is the son of Board Chairman Michael Farkas.
Balance Labs, Inc. reported a change in its board of directors. On December 12, 2025, director Carmen Villegas resigned from the board effective immediately.
The company states that Ms. Villegas’s decision to step down was not due to any disagreement with Balance Labs regarding its operations, policies, practices, controls, or financial-related matters. The filing does not describe any replacement or additional board changes.
Balance Labs, Inc. reported a larger net loss as it restructured leadership and recognized a new derivative tied to its CEO agreement. Net loss was $3,594,664 for Q3 2025 (basic and diluted EPS $0.16 loss) and $3,747,212 for the nine months ended September 30, 2025. Operating cash outflow was $93,487 for the nine months.
Liquidity remains strained: cash was $4,512 as of September 30, 2025, with a working capital deficit of $8,675,685 and an accumulated deficit of $9,630,533. Management disclosed substantial doubt about continuing as a going concern. A derivative liability of $3,297,695 was recognized from an anti‑dilution feature in the CEO’s employment agreement, with a $3,425,796 loss recognized and a $128,101 remeasurement gain in the quarter.
The company issued 780,264 shares to its CEO as part of an initial equity grant, recognizing $142,633 in stock‑based compensation in Q3. As a subsequent event, outstanding debt totaling $4,166,946.69 was converted into common stock at $0.25 per share, and the Board approved additional equity issuances at the same price. Shares outstanding were 46,852,319 as of November 13, 2025.